---
ver: rpa2
title: Heterogeneous graph attention network improves cancer multiomics integration
arxiv_id: '2408.02845'
source_url: https://arxiv.org/abs/2408.02845
tags:
- feature
- heterogatomics
- each
- features
- cancer
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: HeteroGATomics addresses the challenge of integrating multiomics
  data for cancer diagnosis, particularly when dealing with high-dimensional feature
  spaces and small patient cohorts. It introduces a novel approach that combines joint
  feature selection using a multi-agent system (MAS) with heterogeneous graph attention
  networks (GAT).
---

# Heterogeneous graph attention network improves cancer multiomics integration

## Quick Facts
- **arXiv ID**: 2408.02845
- **Source URL**: https://arxiv.org/abs/2408.02845
- **Reference count**: 40
- **Primary result**: AUROC scores of 0.961 (BLCA), 0.766 (LGG), and 0.961 (RCC) on cancer datasets

## Executive Summary
HeteroGATomics introduces a novel approach for integrating multiomics data in cancer diagnosis, addressing challenges of high-dimensional feature spaces and small patient cohorts. The method combines multi-agent system (MAS) based joint feature selection with heterogeneous graph attention networks (GAT) to capture both intra- and cross-modality interactions. Experiments on three cancer datasets demonstrate consistent outperformance of state-of-the-art methods, with significant AUROC improvements across bladder cancer (BLCA), lower-grade glioma (LGG), and renal cell carcinoma (RCC).

## Method Summary
The approach employs a two-stage architecture where joint feature selection is performed using a multi-agent system across all omics modalities simultaneously, capturing complex interactions within and between modalities. Following feature selection, heterogeneous graphs are constructed combining feature and patient similarity networks, enabling more expressive learning of omic-specific representations. A heterogeneous graph attention network then encodes these graphs, with a late fusion strategy integrating predictions across modalities to produce final cancer diagnosis predictions.

## Key Results
- Achieved AUROC scores of 0.961 for BLCA, 0.766 for LGG, and 0.961 for RCC
- Consistently outperformed state-of-the-art multiomics integration methods across all tested cancer types
- Identified known and novel cancer-related genes through biomarker analysis

## Why This Works (Mechanism)
The method succeeds by simultaneously addressing feature selection and representation learning challenges inherent in multiomics data. The multi-agent system enables coordinated feature selection across modalities, preventing redundancy while preserving complementary information. Heterogeneous graph construction captures both feature-feature and patient-patient relationships, while the attention mechanism allows the model to learn which relationships are most informative for classification.

## Foundational Learning
- **Multi-agent systems for feature selection**: Distributed decision-making agents select features across omics modalities, enabling coordinated selection that captures cross-modality dependencies
- **Heterogeneous graph attention networks**: GAT variants that operate on graphs with multiple node and edge types, allowing different attention mechanisms for different relationship types
- **Late fusion strategies**: Combines predictions from modality-specific models rather than early fusion of raw features, preserving modality-specific patterns
- **Joint feature selection**: Simultaneous selection across multiple omics types to identify complementary features while avoiding redundancy
- **Feature-patient similarity networks**: Constructs relationships between features and patients to capture how features relate to specific patient phenotypes

## Architecture Onboarding

**Component map**: MAS Feature Selection -> Heterogeneous Graph Construction -> GAT Encoding -> Late Fusion Prediction

**Critical path**: The MAS performs joint feature selection, reducing dimensionality while preserving cross-modality relationships. Heterogeneous graphs are then built from selected features and patient data, capturing both feature-feature and patient-patient similarities. The GAT module learns attention-weighted representations from these graphs, and late fusion combines modality-specific predictions.

**Design tradeoffs**: Joint feature selection via MAS requires more computational resources but captures cross-modality dependencies better than independent selection. Late fusion preserves modality-specific information but may miss early interactions between modalities. The heterogeneous graph approach handles multiple relationship types but increases model complexity.

**Failure signatures**: Poor performance may indicate that the MAS is selecting irrelevant features, the heterogeneous graph construction is failing to capture meaningful relationships, or the attention mechanism is unable to identify informative connections. Overfitting is a particular risk given the small sample sizes typical of cancer cohorts.

**3 first experiments**:
1. Compare MAS joint feature selection against independent feature selection per modality
2. Evaluate performance with homogeneous vs. heterogeneous graph representations
3. Test early fusion against late fusion strategies for combining modality predictions

## Open Questions the Paper Calls Out
The paper does not explicitly identify open questions for further research.

## Limitations
- Limited evaluation scope with only three cancer types and relatively small sample sizes
- Additional hyperparameters introduced by the multi-agent feature selection component may affect reproducibility
- Claims of consistent outperformance lack comparison with the full spectrum of existing multiomics integration methods
- Assumption that feature-patient similarity networks capture meaningful biological relationships requires further validation

## Confidence
- Method innovation and technical implementation: High
- Performance claims relative to specific benchmarks: Medium
- Biological interpretability of identified biomarkers: Low to Medium

## Next Checks
1. Test HeteroGATomics on additional cancer types with larger sample sizes to assess scalability and robustness
2. Conduct systematic ablation studies isolating the contribution of the multi-agent feature selection component
3. Perform independent validation of identified biomarkers using external biological databases and experimental data